Neglected Diseases

Products to combat neglected diseases in low-income countries generate low profit margins and—without an obvious end market—research and development tend to be underfunded. In recent years, R&D funding for neglected diseases has remained low—$3.1 billion in 2010—and substantially less than the almo...

In this Wonkcast, originally posted on July 2010, Tom Bollyky explains the problems that motivated him in establishing CGD’s Clinical Trials and Regulatory Pathways Working Group. The group’s final report, Safer, Faster, Cheaper: Improving Clinical Trials and Regulatory Pathways to Fight Neglected D...